An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes

Proteome Science

Research

Christoph Grabmer¹  Philipp Mahlknecht²  Markus Reindl²  Christoph Scherfler²  Fabienne Sprenger²  Klaus Seppi²  Werner Poewe²  Gregor K Wenning²  Eva Hametner²  Sylvia Stemberger²  Rudolf Kirchmair³  Johannes Rainer⁴ 

[1] Central Institute for Blood Transfusion and Division for Immunology, University Hospital Innsbruck, Innsbruck, Austria;Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria;Department of Internal Medicine I, Innsbruck Medical University, Innsbruck, Austria;Division of Molecular Pathophysiology, Biocenter, Innsbruck Medical University, and Tyrolean Cancer Research Institute, Innsbruck, Austria;

关键词: Multiple System Atrophy;    Progressive Supranuclear Palsy;    Progressive Supranuclear Palsy;    Serum Prolactin Level;    Progressive Supranuclear Palsy Patient;   

DOI  :  10.1186/1477-5956-10-71

 received in 2012-08-02, accepted in 2012-11-19,  发布年份 2012

来源: Springer

【 摘 要 】

BackgroundMicroarray technology may offer a new opportunity to gain insight into disease-specific global protein expression profiles. The present study was performed to apply a serum antibody microarray to screen for differentially regulated cytokines in Parkinson's disease (PD), multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS).ResultsSerum samples were obtained from patients with clinical diagnoses of PD (n = 117), MSA (n = 31) and PSP/CBS (n = 38) and 99 controls. Cytokine profiles of sera from patients and controls were analyzed with a semiquantitative human antibody array for 174 cytokines and the expression of 12 cytokines was found to be significantly altered. In a next step, results from the microarray experiment were individually validated by different immunoassays. Immunoassay validation confirmed a significant increase of median PDGF-BB levels in patients with PSP/CBS, MSA and PD and a decrease of median prolactin levels in PD. However, neither PDGF-BB nor prolactin were specific biomarkers to discriminate PSP/CBS, MSA, PD and controls.ConclusionsIn our unbiased cytokine array based screening approach and validation by a different immunoassay only two of 174 cytokines were significantly altered between patients and controls.

【 授权许可】

Unknown   
© Mahlknecht et al.; licensee BioMed Central Ltd. 2012. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.